JNJ-78436735
PreclinicalBiologic
JNJ-78436735 is one of 16 biologic programs targeting COVID-19. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
317 competitors in COVID-19
#DrugCompanyPhaseTrials
1Blood Taken
HHospices Civils de Lyon
Preclinical
Other Tkis
BayerPreclinical
Serology
UUniversity Hospital Center of Martinique
Preclinical
Pfizer-Biontech COVID-19 MRNA Vaccine
PfizerPreclinical
Huashi Baidu Granule
XXiyuan Hospital of China Academy of Chinese Medical Sciences
Preclinical
Administration of Almitrine
CCentre Hospitalier Universitaire de Nice
Preclinical
Tpa
UUniversity of Florida
Preclinical
Thrombolytic
FFaculty Hospital Kralovske Vinohrady
Preclinical
Coronavac COVID-19 Vaccine
HHospital Moinhos de Vento
Preclinical
SARS-Cov-2 Bivalent MRNA Vaccine
AAIM Vaccine Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for JNJ-78436735. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- MMasaryk University